Updated May 2026 · SEC EDGAR data
Merck & Co. Inc., Q2 2024 Earnings
Healthcare · Period ending 2024-06-30
Merck & Co. Inc. (MRK) reported Q2 2024 earnings to the SEC: revenue of $16.1B, EPS of $2.14, and net income of $5.5B. Sourced directly from Merck & Co. Inc.'s SEC EDGAR XBRL filings. Sector: Healthcare.
Headline Numbers
Q2 2024 in Context
Merck & Co. Inc.'s Q2 2024 revenue rose 2.1 percent versus the prior quarter, signaling sequential momentum.
That works out to a 33.9 percent net margin, exceptional profitability that points to scale economics, dominant market position, or particularly favorable product mix.
The NEUTRAL Operator Read
Across the 8 quarters tracked, Merck & Co. Inc. carries an operator signal of NEUTRAL with high confidence. Recent quarters are roughly flat; management commentary is steady-state. No major directional signal for operators in adjacent markets.
How This Data Was Sourced
All numbers on this page come directly from Merck & Co. Inc.'s SEC EDGAR filing for Q2 2024. EDGAR is the U.S. Securities and Exchange Commission's public filing system; quarterly results are filed on Form 10-Q and annual results on Form 10-K. XBRL tagging ensures revenue means revenue across every filer. The earnings press release is typically furnished as a Form 8-K. Both forms are public domain. Read the methodology for the operator-signal classification rules.
Frequently Asked Questions
What did Merck & Co. Inc. report in Q2 2024?
Merck & Co. Inc. reported revenue of $16.1B, EPS of $2.14, and net income of $5.5B for Q2 2024. Figures come from the company's SEC EDGAR XBRL filing.
Where does this earnings data come from?
All numbers on this page are pulled directly from Merck & Co. Inc.'s SEC EDGAR XBRL filing for Q2 2024 (Form 10-Q for quarterly results, Form 10-K for annual). EDGAR is the SEC's public filing system; XBRL is a structured tagging standard that ensures revenue means revenue across every filer. Data is in the public domain.
What is Merck & Co. Inc.'s current operator signal?
Merck & Co. Inc. currently carries a NEUTRAL operator signal with HIGH confidence. The signal is calculated across all available quarters, not just this one, and combines a quantitative read of revenue trajectory with a qualitative read of management commentary. Read the methodology page for the formal classification rules.
Is this earnings analysis investment advice?
No. EarningsCallAI is built for business operators evaluating market trends, demand signals, and competitive dynamics, not for stock trading decisions. Operator signals are not buy/sell recommendations. Always consult a licensed financial advisor before making investment decisions.
When was the Q2 2024 report filed?
Merck & Co. Inc. filed its Q2 2024 results to the SEC for the period ending 2024-06-30. Quarterly filings (10-Q) are typically due within 40 days of period end for large accelerated filers; annual reports (10-K) are typically due within 60 days.
Merck & Co. Inc. (MRK) reported Q2 2024 earnings to the SEC: revenue of $16.1B, EPS of $2.14, and net income of $5.5B. Sourced directly from Merck & Co. Inc.'s SEC EDGAR XBRL filings. Sector: Healthcare.